Why Do Standard Endoscopies Miss Diffuse Gastric Cancer?

It is incredibly frustrating—and unfortunately common—to learn that a routine endoscopy performed just months ago missed your stomach cancer. The reason this happens is not necessarily because the doctor made a mistake, but because of how this specific cancer behaves. Diffuse gastric adenocarcinoma (DGC) grows beneath the stomach lining rather than forming a visible lump or ulcer on the surface. Because a standard endoscopy looks at the inside surface of the stomach and takes very shallow samples, it can completely miss the cancer growing in the deeper layers ^[1][2].

The Biology of Diffuse Gastric Cancer

To understand why DGC is so stealthy, it helps to know how it grows. Most stomach cancers form distinct masses or tumors. DGC, however, is characterized by an infiltrative growth pattern ^[3][2].

• Signet ring cells: This cancer is often made up of specialized cells called signet ring cells, which scatter and spread outward through the tissue rather than clumping together into a single lump ^[4][5].
• Submucosal growth: Instead of growing on the mucosa (the innermost layer of the stomach wall facing the inside of the stomach), these cells penetrate deeper into the submucosal and muscle layers of the stomach wall ^[3][2].
• Linitis Plastica: As the cancer spreads through these deeper layers, it can cause a condition known as linitis plastica ^[1][6]. This means the stomach wall becomes thick, stiff, and rigid, like a leather bottle, rather than forming a visible mass ^[1][6].

Why Standard Endoscopy Often Fails

A standard upper endoscopy (also called an EGD) is an excellent tool for finding ulcers, inflammation, or traditional tumors on the stomach lining. During the procedure, the doctor passes a camera into the stomach and uses tiny forceps to snip off pieces of tissue for a biopsy.

However, because DGC cells grow deep in the stomach wall, the surface mucosa often looks perfectly healthy and normal to the camera ^[6][2]. Even if the doctor takes standard biopsies, the tiny forceps only scrape the superficial top layer of the stomach lining ^[7]. The resulting pathology report will often come back completely clear, resulting in a false negative ^[8][7].

Because the cancer causes the stomach to become rigid, the only clue during a standard endoscopy might be poor distensibility—a medical term meaning the stomach doesn’t stretch or inflate properly when the doctor pumps air into it. Still, without specialized tools, capturing the actual cancer cells is remarkably difficult.

Specialized Tools: Digging Deeper for a Diagnosis

When you experience persistent, stealthy symptoms of DGC—such as feeling full after only a few bites of food (early satiety), vague nausea, or unexplained weight loss—and standard biopsies are clear, doctors must rely on advanced techniques to look beneath the surface. This is especially true if you are undergoing surveillance for a known genetic risk, such as a CDH1 mutation ^[4][5].

Endoscopic Ultrasound (EUS) is one of the most effective ways to detect this cancer. It attaches a tiny ultrasound wand to the end of the endoscope ^[6][9].

• Seeing the deep layers: The ultrasound uses sound waves to create a cross-sectional picture of the entire stomach wall, allowing the doctor to see the thickened submucosal muscle layers where the DGC is hiding ^[6][10].
• Deep tissue sampling: Once the thickened area is located, the doctor performs an EUS-FNA (Fine Needle Aspiration) or EUS-FNB (Fine Needle Biopsy) ^[9][7]. A hollow needle is passed through the healthy surface lining directly into the deeper tissue to extract the hidden cancer cells ^[8][7].

While EUS with deep biopsy is a primary tool, doctors may also use bite-on-bite biopsies (taking multiple samples from the exact same spot to dig a tiny “tunnel” into the tissue) or a diagnostic laparoscopy (a minimally invasive surgery to view the outside of the stomach) to confirm the diagnosis.

Once these specialized methods reveal the presence of diffuse gastric adenocarcinoma, the focus can safely shift to accurate staging and assembling a multidisciplinary oncology team to plan the most effective next steps.